# A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions

> **NCT06744127** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 58 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** BR1015
- **DRUG:** BR1015-1
- **DRUG:** BR1015-2

## Key facts

- **NCT ID:** NCT06744127
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-03
- **Primary completion:** 2025-03-14
- **Final completion:** 2025-03-14
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06744127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06744127, "A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06744127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*